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Abstract
Background: Enteropathogenic E. coli (EPEC) and enterohemorrhagic E. coli (EHEC) are two categories of E. coli strains
associated with human disease. A major virulence factor of both pathotypes is the expression of a type three secretion
system (TTSS), responsible for their ability to adhere to gut mucosa causing a characteristic attaching and effacing lesion (A/
E). The TTSS translocates effector proteins directly into the host cell that subvert mammalian cell biochemistry.
Methods/Principal Findings: We examined synthetic peptides designed to inhibit the TTSS. CoilA and CoilB peptides, both
representing coiled-coil regions of the translocator protein EspA, and CoilD peptide, corresponding to a coiled–coil region
of the needle protein EscF, were effective in inhibiting the TTSS dependent hemolysis of red blood cells by the EPEC E2348/
69 strain. CoilA and CoilB peptides also reduced the formation of actin pedestals by the same strain in HEp-2 cells and
impaired the TTSS-mediated protein translocation into the epithelial cell. Interestingly, CoilA and CoilB were able to block
EspA assembly, destabilizing the TTSS and thereby Tir translocation. This blockage of EspA polymerization by CoilA or CoilB
peptides, also inhibited the correct delivery of EspB and EspD as detected by immunoblotting. Interestingly, electron
microscopy of bacteria incubated with the CoilA peptide showed a reduction of the length of EspA filaments.
Conclusions: Our data indicate that coiled-coil peptides can prevent the assembly and thus the functionality of the TTSS
apparatus and suggest that these peptides could provide an attractive tool to block EPEC and EHEC pathogenesis.
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Introduction
Enteropathogenic E. coli (EPEC) and enterohemorrhagic E. coli
(EHEC) are associated with diarrhea in humans. EPEC is a major
cause of infantile diarrhea in developing countries [1] and EHEC
is responsible for disease whose clinical spectrum includes
diarrhea, hemorrhagic colitis and hemolytic uremic syndrome
(HUS), the leading cause of renal failure in children in Argentina
and several other countries [2,3,4]. Shiga toxin expression from
integrated bacteriophages in EHEC strains [2,5] is considered
responsible for both hemorrhagic colitis and HUS. The main
reservoir of EHEC is healthy cattle although a limited number of
serogroups have been associated with diarrhea in young calves
[5,6,7,8].
Both categories of E. coli, EPEC and EHEC, are known to carry
a locus of enterocyte effacement pathogenicity island (LEE)
[9,10,11]. The LEE encodes a type III secretion system (TTSS)
[12] that injects effector proteins into enterocytes, some of which
alter signaling pathways. This process results in the formation of
‘‘attaching and effacing’’ (A/E) lesions on intestinal epithelia,
which are characterized by the intimate adhesion of bacteria to
actin-rich pedestals and a localized destruction of microvilli. The
TTSS is a complex structure of more than 20 proteins forming a
‘needle and syringe’ apparatus that allows effector proteins to be
injected directly into the host cell [13,14,15].
The LEE has been completely sequenced and contains five
major operons: LEE1, LEE2, LEE3, LEE4 and LEE5.E s p A
[16], EspB and EspD [17] are some of the proteins encoded by
LEE4 that make up the translocon portion of the TTSS [11,18].
EspA makes hollow, filamentous appendages surrounding the
bacteria, which are present in a transient manner [18]. These
structures form a translocation tube that acts as a channel to
deliver proteins from the bacteria into the intestinal cell. EspB
and EspD are involved in pore formation on the membranes of
the infected cells [19] and are translocated to both the
membrane and the cytoplasm [20]. Complexes formed by
EspA, EspB and EspD proteins may participate in the initial
step of bacterial adherence [21]. The proximal end of the EspA
filament rests in the EscF needle near the basal body of the
TTSS [22]. EscF is also encoded in LEE4. LEE5 encodes the
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intimate attachment of the bacteria to host enterocytes, and its
own receptor Tir, which is translocated through the TTSS into
the host cell surface [23].
Coiled-coil regions are involved in protein-protein interaction,
especially in the formation of multimeric complexes and molecular
recognition [24,25]. Coiled-coil regions comprise alpha-helices
interlaced around each other in a highly organized manner. A
regular sequence pattern known as the heptad repeat, a seven-
residue pattern denoted abcdefg in which the a and d residues are
hydrophobic, is the basis of coiled coils. Coiled-coil sequences have
an important role in the formation of TTSS structures [26,27].
The carboxy terminus of EspA comprises an alpha-helical region
which demonstrates heptad periodicity. Site-directed mutagenesis
of EspA heptad residues has generated EPEC mutants defective in
EspA filament assembly, indicating that coiled-coil interactions are
essential in the assembly of EspA filament associated with the
TTSS [27]. In this study, we designed synthetic peptides
corresponding to coiled-coil domains of EspA, EscF and to the
intimin interacting region of Tir, which were tested for inhibiting
the action of TTSS.
Results
Designed Peptides Inhibit TTSS-Mediated RBC Lysis
Many TTSS protein are predicted to share a common coiled-
coil structural feature. In fact, the coiled-coil domain of EspA is
required for assembly of the EspA filament-associated type III
secretion translocon [25]. Therefore, peptides were designed to
target coiled-coil domains in EspA and EscF. The coiled-coil
region of EspA contains 30 aa. To better discriminate domains
inside this region two 15-aa peptides were designed. CoilA and
CoilB peptides contain 15 aa corresponding to coiled-coil domains
at the C-terminal end of EspA [26,15]. CoilC and CoilD represent
N-terminal coiled-coil domains of EscF [15] and PepTir peptide
represents the interaction region between Tir and its ligand,
intimin [28] (Table 1).
Twelve-well plates containing peptides and bacteria were
incubated for 1 h to allow their interaction. A 5% suspension of
RBC was then added, plates were incubated for another 3 h, and
supernatants were monitored for released hemoglobin. The
EPEC E2348/69 strain produced hemolysis (referenced as
100%), whereas EPEC DescN, a mutant that does not synthesize
the TTSS, produced only 3% lysis, which is usual for a non-
pathogenic strain (E. coli K-12), thus indicating that the RBC lysis
was due to the TTSS (Fig. 1A). CoilA and CoilB peptides
inhibited around 95% of the TTSS-mediated RBC lysis caused
by the E2348/69 strain; this inhibitory effect was not synergistic
since preincubation of EPEC with both peptides also caused a
hemolysis inhibition of 95% (Fig. 1A). Other coiled-coil
structures, such as CoilD, reduced the hemolysis by only 25%.
Interestingly, in all cases, the inhibitory effect was observed only
when the bacteria were preincubated with the corresponding
peptide, since peptides did not reduce the hemolysis when added
to the bacteria at the same time as RBC. On the other hand,
CoilC (Fig. 1) and PepTir (data not shown) did not show
inhibitory activity. Inhibition of hemolysis caused by EPEC due
to CoilA and CoilB peptides was dose-dependent since a
Table 1. Characteristics of designed peptides.
Name Target Sequence
CoilA C-terminal Sequence of EspA [LTTTVNN][SQLEIQQ]M
CoilB C-terminal Sequence of EspA [MSNTLNL][LTSARSD]M
CoilC N-terminal Sequence of EscF LSDSVPELLNSTDLV
CoilD N-terminal Sequence of EscF VNDPEKMLELQFAVQ
PepTIR Tir KVNIDENGNAI
Heptads is shown between square brackets and the a position of heptads is in
bold.
doi:10.1371/journal.pone.0009046.t001
Figure 1. Coiled-coil peptides effectively inhibit RBC hemolysis promoted by EPEC. (A) Hemolysis of sheep RBC observed with EPEC
bacteria preincubated with coiled-coil peptides. Results are presented as percentage relative to hemolysis (6 standard deviation) observed upon
incubation of RBC with EPEC alone. K12 means the hemolysis caused by the E. coli non-pathogenic strain. (B) Doses-dependent effect of CoilA and
CoilB peptides on the hemolysis of RBC. The peptides were applied to the RBC-E2348/69 system to various concentrations and a dose-dependent
response was observed. pH represent a mock control to rule out the biological influence of alkaline pH used to dissolve peptides. Each assay was
done by triplicate.
doi:10.1371/journal.pone.0009046.g001
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a 50% of hemolysis. We chose to use peptides at 0.56 mg/ml in
spite of the fact that a concentration of 0.36 mg/ml is enough to
cause 90% of inhibition (Fig. 1B).
Designed Peptides Inhibit the Formation of A/E Lesions
Since CoilA, CoilB and CoilD were able to inhibit the
hemolysis caused by EPEC, which could involve translocator
proteins at cell membrane level, we decided to explore whether
peptides were also able to block effector proteins delivery and
thus prevent the formation of A/E lesions in epithelial cells. Thus,
peptides interfering in actin polymerization beneath E2348/69
strain adhering to HEp-2 cells were visualized by FAS
(fluorescent actin staining). As expected, EPEC bacteria were
able to induce actin polymerization for pedestal formation in
almost all the cells (Fig. 2A), the A/E lesions were not seen in
uninfected cells (Fig. 2B). CoilA or CoilB preincubation with
EPEC caused a decrease in pedestal formation in epithelial cells,
showing different effectiveness (Fig. 2C and Fig. 2D). A
morphometric study of different fields by confocal microscopy
showed that CoilB peptide strongly inhibited the A/E lesion
formation by EPEC, reducing the number of HEp-2 cells
showing pedestals to 2% (P,0.01), as compared with untreated
cells (EPEC without peptides), where 80% of cells had pedestals
(Fig. 2E). On the other hand, CoilA reduced pedestal-forming
cells to 20% (P,0.01), whereas CoilD was unable to inhibit
pedestal formation in HEp-2 cells (Fig. 2E) and the percentage of
Fas-positive cells was similar to those cells treated with EPEC at
the pH used to dissolve the peptides.
Designed Peptides Interfere with EspA Polymerization
and Tir Translocation
Since both peptides, CoilA and CoilB, are directed against
EspA and inhibited pedestal formation, we determined their
efficiency to block EspA polymerization and thereby Tir
translocation. For that, HEp-2 cells were treated with EPEC
preincubated either with or without CoilA or CoilB, and EspA
and Tir were then visualized using specific antibodies and
confocal microscopy. A drastic decrease in the secreted EspA
(Fig. 3B) and translocated Tir (Fig. 3D) was observed in bacteria
preincubated with CoilA. Similar results were obtained when
CoilB was used (data not shown). In HEp-2 cells monolayers
treated with EPEC without peptides, as expected, expression of
EspA on the infecting bacteria was detected (Fig. 3A) and
colocalization of Tir and F-actin was observed (Fig. 3C). A HEp-
2 detaching activity by EPEC was observed in control cultures. In
contrast, this cytopathic effect was absent when bacteria were
preincubated with CoilA or CoilB peptides (data not shown).
Furthermore, we observed that peptides did not inhibit the
growth of E2348/69 in LB media (data not shown). We also
noticed that coiled-coil peptides decreased the EPEC adherence
to HEp-2 cells by detecting more non-adherent bacteria in the
supernatant of HEp-2 cells treated with EPEC plus CoilA (7 fold)
or CoilB (40 fold) than in cells treated with EPEC but without
peptides (data not shown).
To further determine the effect of CoilA and CoilB on EspA
polymerization and Tir translocation were also examined by
Western blotting. For that, HEp-2 cells were treated for 2 h with
either EPEC alone or preincubated with each of the peptides and
exhaustively washed. Cell extracts were prepared and the contents
of EspA and Tir (Fig. 4) analyzed by Western blot using specific
antibodies. CoilA and CoilB drastically decreased the amount of
EspA associated to the cells and attached bacteria (Fig. 4), but,
more importantly, the amount of EspA species detected as EspA
polymers (see arrowhead in Fig. 4). These effects correlated with a
significant decrease of Tir in the cells (Fig. 4) from the same
preparations. The effective amount of EspA and Tir associated per
cell may be even higher in non-treated (without peptides) cell
cultures because it could be underestimated as some HEp-2 cells
are detached from the surface upon infection. The pH buffering
Figure 2. Coiled-coil peptides inhibit A/E lesion formation caused by EPEC. HEp-2 cells were incubated with EPEC E2348/69 either with or
without coiled-coil peptides. Fluorescent actin staining polymerization was revealed using rhodamine phalloidin (red) and TO-PRO-3 to stain bacterial
and eukaryotic DNA (blue) and imaged by confocal microscopy. Incubation of HEp-2 cells with the wild type EPEC E2348/69 strain without peptides
(EPEC WT); preincubated with CoilA (EPEC+CoilA), or CoilB (EPEC+CoilB) peptide and uninfected cells. The corresponding percentage of HEp-2 cells
carrying pedestals, obtained by examining 100 cells, is shown in panel E. EPEC pH represents a mock control to rule out the biological influence of
alkaline pH used to dissolve peptides; PBS at alkaline pH was used in volumes identical to those in which peptides were added to HEp-2 cells.
doi:10.1371/journal.pone.0009046.g002
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the results were similar to the positive control (Fig. 4).
To determine whether CoilA and CoilB peptides have an effect
on protein secretion by the TTSS in vitro, EPEC bacteria were
incubated for 4 h either with or without peptides, in the same
conditions as for RBC lysis and pedestal formation assays, and
EspA, EspB, EspD and Tir proteins were sought in supernatants
and bacterial lysates. Bacterial lysates or supernatants of E2348/69
cultures incubated with CoilA or CoilB peptides showed similar
amounts of cell-associated and secreted EspA, comparable with
the amounts showed by bacteria incubated without peptides, as
determined by Western blotting (Fig. 5). In contrast, preincubation
of bacteria with CoilB blocked the secretion of EspB to the culture
supernatant (Fig. 5). This effect was not clearly observed with
CoilA. On the other hand, secretion of EspD was affected by both
peptides, CoilA and CoilB, and the protein was detected in the
pellet of lysed bacteria. CoilA or CoilB lightly decreased the
secretion of Tir. The fact, that CoilA and CoilB did not affect the
intrabacterial content of Esp proteins indicates that gene
expression of these proteins is not distorted by coiled-coil peptides.
As expected, the DescN strain a mutant that does not synthesize the
TTSS showed no EspA in culture supernatants, thus confirming
the absence of bacterial lysis (data not shown).
CoilA Peptide Blocks Formation of EspA Filaments on the
Bacteria
Since coil peptides are able to inhibit the TTSS by blocking
EspA polymerization, we expected a decrement in EspA filaments
on the bacterial cell surface upon incubation with coil peptides. To
assess this hypothesis, EPEC was subjected to immunogold
staining after in vitro induction of TTSS-synthesis in either the
presence or absence of CoilA peptide, since Coil B has a tendency
to precipitate forming clumps that interfere with the quality of
electron micrographs. Indeed, transmission electron microscopy
analysis showed EspA filaments with an average length of
7006150 nm displayed on EPEC bacteria, which were detected
by anti-EspA and immunogold. Interestingly, bacteria preincu-
bated with CoilA showed shorter EspA filaments, which were
reduced to a length of about 250650 nm (Fig. 6). This result
correlates with the observed reduction in EspA protein as
monomer and polymer species in lysed cells infected with EPEC
in the presence of either CoilA or CoilB peptides (see Fig. 4).
Figure 3. Coiled-coil peptides inhibit EspA polymerization and Tir translocation. Confocal microscopy images (1000X magnification)
showing fluorescence on HEp-2 cells infected with EPEC E2348/69 and either with or without coiled-coil peptides. Incubation of HEp-2 cells with (A)
the wild type EPEC E2348/69 strain, without peptides. Actin was revealed by FAS using rhodamine-phalloidin (red) and EspA polymers by anti EspA
sera (green); (B) the wild type EPEC E2348/69 strain preincubated with CoilA peptide, staining as in A; (C) the wild type EPEC E2348/69 strain, without
peptides. Actin was revealed by FAS using rhodamine-phalloidin (red) and Tir by anti Tir sera (green). Colocalization of F-actin and Tir appears as
yellow; (D), the wild type EPEC E2348/69 strain preincubated with CoilA peptide, staining as in C. The insets (magnification 5000 x) show additional
details.
doi:10.1371/journal.pone.0009046.g003
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Various pathogenic bacteria use related virulence systems,
contradicting the long-held paradigm that each bacterium has a
unique mode of action. These findings have implications for
development of novel antibacterial agents as well as research
aimed at understanding bacterial virulence. The type III secretion
systems are virulence mechanisms developed by many Gram-
negative pathogenic bacteria to introduce effector proteins into the
cytoplasm of eukaryotic cells. In all relevant model systems tested
thus far, mutating or deleting a part of the TTSS significantly
decreases the virulence of the affected pathogen. Presumably,
chemical compounds that specifically inhibit the type III system
may prevent disease by impairing essential virulence properties
within this system. Thus, this strategy to target virulence is
attractive [29,30,31]. A general method used today within the
pharmaceutical industry and academia to find starting points for
drug development is to screen large collections of compounds in
various assays [32]. These large-scale screens are generally termed
high-throughput screening [33]. Hits from the screening are
further evaluated to verify that the identified response is not due to
side effects (false positives). With this complicated method, it is
possible to identify small-molecule virulence inhibitors in the
absence of target structural information. However, since the TTSS
was first identified, important advances have been achieved in
understanding the genetics, structure and function of the TTSS
[13]. Thereby, in this work we designed peptides with sequences
derived from coiled-coil sequences from main components of the
TTSS from EPEC and EHEC. We found that CoilA and CoilB
were able to block EspA assembly, thus destabilizing the TTSS
and Tir translocation, as well as inhibiting EspB and EspD
secretion.
Figure 4. CoilA and CoilB peptides block EspA polymerization
and Tir translocation. Cell monolayers were infected with bacteria
pretreated with peptides, washed, and lysed for Western blot detection
of EspA and Tir proteins with specific rabbit antisera. pH represents a
mock control to rule out the biological influence of alkaline pH used to
dissolve peptides; PBS at alkaline pH was used in a volume identical to
those in which peptides were added to HEp-2 cells.
doi:10.1371/journal.pone.0009046.g004
Figure 5. Coiled-coil peptides affect the secretion of EspB and
EspD but not EspA secretion. EPEC E2348/69 bacterial cultures were
incubated in the presence of CoilA or CoilB peptides and concentrated
supernatants and bacterial extracts were analyzed by Western blotting
using specific antisera directed to EspA, EspB, EspD or Tir. The same
amount of cell monolayer was loaded in each lane. pH represents a
mock control to rule out the biological influence of alkaline pH used to
dissolve peptides. PBS at alkaline pH was used in volumes identical to
those in which peptides were added to cultures.
doi:10.1371/journal.pone.0009046.g005
Figure 6. CoilA peptide blocks the formation of EspA filaments.
Immunogold EM of EspA filaments on EPEC cultures incubated either
with or without CoilA peptide. After incubation of bacterial samples
with specific rabbit anti-EspA serum, the samples were observed by
TEM. EPEC alone, without peptides (A, C) and EPEC incubated with
CoilA (B, D). Bars, 200 nm (A, B), or 100 nm (C, D). Yellow box frames
show EspA filaments.
doi:10.1371/journal.pone.0009046.g006
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TTSS has been identified both in Yersinia spp. after screening a
library of 9,400 compounds [34,35] and in EPEC after screening
20,000 compounds [36]. In addition, the same or similar
compounds have also been shown to inhibit the TTSS in
Chlamydia trachomatis [37] and Salmonella TTSS-1 [38]. Howev-
er, this compound was initially identified in a phenotype-based
reporter-gene assay and, although additional studies have
indicated TTSS specificity, the target protein is still unknown
[39]. Here we specifically designed 15-aa peptides based on the
coiled-coil structure of components of the TTSS of EPEC and
EHEC bacteria. CoilB, which was designed to block the last 15
aa of the coiled-coil structure in the C-terminus of EspA, was the
most efficient peptide in inhibiting EspA polymerization, while
CoilA, which was designed to block the first 15 aa of the same
coiled-coil structure, was less efficient than CoilB. Interestingly,
CoilC and CoilD, which were designed to block the coiled-coil
structure of EscF, were unable to block the A/E lesion, although
CoilD showed a small effect of blocking the hemolysis by EPEC.
At present, it is not clear whether both peptides are effective in
preventing the coiled-coil association of EscF with itself and/or
with EspA or whether that association is stronger than that of
EspA multimerization. PepTir was ineffective in the hemolytic
assay, which is in agreement with previous reports indicating that
Tir is not necessary for RBC lysis [44]. The effect of PepTir
should be tested in the future in FAS assays. These data suggest
that the effects of the coiled-coil peptides are related to their
availability during TTSS formation (i.e. during EspA polymer-
ization instead of interfering in EscF and EspA interaction), as
indicated by the fact that peptides are effective only when added
to bacteria that are growing TSSS and not once it is already
formed. It has been previously demonstrated that non-conser-
vative amino acid substitution of specific EspA heptad residues in
the coil structure generates EPEC mutants defective in filament
assembly but which retain the ability to induce A/E lesions; an
additional mutation can totally abolish EspA filament assembly
and A/E lesion formation [26]. In the present work, we showed
that CoilA and CoilB interfere with EspA filament as detected by
confocal and electron microscopy and biochemically; this effect
correlates with the inhibition of Tir translocation and A/E
lesion.
Interestingly, CoilA and CoilB interfering with the EspA:EspA
interaction during the filament formation also blocks the
bacteria:host cells interaction, since in EPEC and EHEC the
type III secreted protein EspA is assembled into a filamentous
organelle that attaches the bacterium to the plasma membrane of
the host cell. Formation of EspA filaments is dependent on the
expression of another type III secreted protein, EspD, which is
involved in the formation of the translocation pore in the host cell
membrane. Although EspD does not appear to be a structural
component of the EspA filament, an EspD EPEC mutant secretes
only low levels of EspA and produces barely detectable EspA
filaments [18]. EspD is translocated into the host cell membrane
and is required for cell attachment [40] and EPEC-induced
hemolysis [44]. Additionally, the carboxy terminus of EspD is
predicted to adopt a coiled-coil conformation with 99%
probability. In fact, there is an EspD-EspD protein interaction
and a radical mutation in the C-terminus coiled-coil domain of
EspD affects EPEC induced A/E lesion formation, EspA
filament-mediated cell attachment, and EPEC induced hemolysis
without affecting EspA filament biosynthesis [27]. Here, we also
found a close relation between EspA and EspD, since CoilA or
CoilB were able to block EspA filament formation as well as
EspD secretion to the spent media. On the other hand, EspB
mutants are unable to translocate Tir [23], thus suggesting that
functional EspB is also required for protein translocation. EspB
can bind and be copurified with EspA [41]. However, formation
of EspA filaments and binding of EspA filaments to the target
host cell can occur even in the absence of EspB [41], thus
suggesting that EspB modulates EspA filament activity and signals
the transition from an adhesive to a translocation function.
Indeed, we found that even though CoilA or CoilB inhibit A/E
lesion formation, only CoilB is able to inhibit EspB secretion to
the spent media; perhaps this effect allows CoilB to inhibit EPEC
infection more efficiently.
CoilA and CoilB peptides seem to have little or no effect in the
in vitro secretion of EspA and Tir (Fig. 5). Particularly interesting
i st h ec a s eo fT i r ,b e c a u s eu p o ncoiled-coil incubation, this
effector protein was barely detected on HEp-2 cells by
microscopy (Fig. 3D) or associated to HEp-2 cell by Western
b l o t( F i g .4 ) .T a k e nt h e s er e s u l t st o g e t h e r ,i ta p p e a r sa si ft h e
translocation, but not the secretion of Tir is affected by coiled-
coil peptides. These observations are congruent with a defect in
the injectosome formation. Further research will clarify this point
as well as whether, upon incubation with coiled coil peptides, tips
of filament are capped with EspB and/or EspD. As EspD is not
secreted in the presence of CoilA or CoilB peptides, EspD is
probably not present in the tip of filaments of bacteria treated
with coiled-coil peptides.
In conclusion, the design of molecules to impair intimate
attachment of attaching and effacing pathogens to the intestinal
mucosa will probably have an important effect on dangerous
microorganisms of public health importance, and there is a
possibility that virulence factor inhibitors will be effective for a long
time before resistance becomes an issue. Research on finding new
inhibitors for novel virulence targets can potentially be used
therapeutically, or preventive as in this case, as well as be a tool for
elucidating the intricate regulatory systems that modulate EPEC
and EHEC virulence or any other bacterial member harboring a
TTSS. Coiled-coil peptides are small molecules easier to
synthesize than complex organic molecules and might be part of
a nutraceutical formulation against diarrheogenic pathogens.
Materials and Methods
Ethics Statement
All research involving animals were conducted according to
relevant national and international guidelines and approved by the
Institutional Animal Care and Use Committee del Centro de
Investigacio ´n en Ciencias Veterinarias y Agrono ´micas del INTA
(CICUAE INTA-CICVyA), Argentina.
Peptides, Bacterial Strains and Growth Media
CoilA, CoilB, CoilC, CoilD and PepTir peptides were
synthesized commercially (Genbiotech, Buenos Aires). Peptides
were solubilized with PBS (pH 10.0). CoilB was not completely
soluble. Due to the alkalinity of the peptide solution, in hemolysis
and FAS experiments, a similar amount of PBS pH 10.0 was used
as a mock control to rule out the influence of pH in the effects
observed. EPEC E2348/69 [42] was kindly provided by Marta
Rivas, ANLIS-Instituto Nacional de Microbiologı ´a Dr. Carlos G.
Malbra ´n, Buenos Aires. The E. coli EPEC E2348/69 DescN strain
[43], a mutant that does not synthesize the TTSS was used as a
negative control in the hemolysis and FAS assays. Bacteria were
grown in Luria Bertani broth (LB) or Dulbecco’s modified Eagle
medium (DMEM) lacking phenol red (Gibco-BRL), without
antibiotics and bovine fetal serum at 37uC without shaking.
Peptides Inhibiting EPEC TTSS
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The possible inhibitory effect of peptides on the hemolytic
activity exhibited by TTSS-encoding E. coli strains [44] was
evaluated. The EPEC E2348/69 strain was grown in LB broth
overnight at 37uC without shaking, OD600 was taken to measure
the number of bacteria, and then diluted 1:100 into Dulbecco’s
modified Eagle medium (DMEM) lacking phenol red (Gibco-BRL)
with 0.56 mg/ml of peptides into 12-well plates. The plates were
incubated for 1 h under a 5% CO2 atmosphere to allow the
interaction between peptides and bacteria. In turn, red blood cells
(RBCs) were separated by centrifugation from fresh defibrinated
sheep blood, which was obtained by jugular vein punction, washed
three times with 10 mM PBS (pH 7.4) and resuspended at 5% in
PBS. Then, 2 ml of the 5% suspension of RBC in PBS was added
to the cultures in the plates and incubated for 3 h at 37uC under a
5% CO2 atmosphere. The suspension was removed from the
plates and centrifuged at 12,0006g for 1 min. Supernatants were
monitored for the presence of released hemoglobin by measuring
the OD at 543 nm.
Immunofluorescence Staining
HEp-2 cells (5610
4) were seeded in eight well chamber slides
(NUNC, Lab-Tek, USA) and incubated at 37uC under a 5% CO2
atmosphere up to 70–90% confluence. Overnight LB culture of
the EPEC E2348/69 strain was diluted 1:20 into 3 ml of DMEM
and cultured for 1 h. CoilA, CoilB or CoilD peptides were then
added to the culture at a concentration of 0.56 mg/ml and
allowed to interact with the bacteria for 1 h at 37uC under a 5%
CO2 atmosphere. Next, the bacteria concentration was adjusted
measuring the OD600 to inoculate HEp-2 cells at a multiplicity of
infection of 7 and 400 ml was added to the washed cells. After 2 h
of interaction at 37uC in 5% CO2, cells were stained as described
by Knutton et al. [45], with minor modifications. Briefly, the
monolayers were gently washed three times with PBS, to eliminate
the non-adherent bacteria, fixed in 4% paraformaldehyde in PBS
for 20 min and permeabilized for 5 min in 0.15% Triton X- 100
in PBS. After three washes with PBS, the cells were stained by
fluorescent actin staining (FAS) with tetramethyl rhodamine iso-
thiocyanate (TRITC)-labeled phalloidin (Molecular Probes Eur-
ope, Leiden, The Netherlands) to stain actin. TO PRO-3 staining
was used to detect eukaryotic nuclei and bacterial DNA
(Invitrogen). In another similar experiments, EspA and Tir
proteins were stained using rabbit specific antibodies obtained
elsewhere [46] and fluorescein isothiocyanate (FITC)-conjugated
goat anti-rabbit IgG (Zymed) as secondary antibody. The cells
were observed under fluorescence microscopy with a confocal laser
microscope (Leica TC SP2).
Immunoblotting
In order to determine the effect of syntethic peptides in the
production and excretion of TTSS-proteins by EPEC, cellular and
supernatants culture extracts of peptide-treated bacteria were
subjected to western blot analysis with specific antisera. The
E2348/69 strain grown overnight at 37uC in LB was diluted 1:100
into 2 ml of DMEM containing CoilA or CoilB peptides at a
concentration of 0.56 mg/ml, respectively, and cultured for
another 4 h in the presence of 5% CO2. After collecting by
centrifugation, bacteria were suspended in 2X SDS sample buffer
and boiled for 5 min. The proteins present in culture supernatants
were precipitated by the addition of trichloroacetic acid at 20%
(wt/vol) and incubated overnight at 4uC. The protein precipitates
were then collected by centrifugation at 20,0006g for 25 min,
washed twice with 200 ml of ice-cold acetone and resuspended in
20 ml Tris-HCl 10 mM pH 8.8. Whole-cell extracts and culture
supernatants were then analyzed by Western blotting using
polyclonal rabbit antibodies against EspA, EspB, EspD and Tir
recombinant proteins as described by Vilte et al [46]. Primary
antibodies were detected with horseradish peroxidase-conjugated
goat anti-rabbit IgG (Sigma Chemical Co., St. Louis, MO) diluted
1:10,000. The immunoblots were revealed with 4-Cl-1-naphthol
(Pierce, Rockford, IL).
EPEC-Secreted Proteins Associated to HEp-2 Cells and
Bacterial Viability
HEp-2 monolayers were inoculated with bacteria pretreated
with CoilA or CoilB peptides as described for fluorescent actin
staining. After infection, the supernatant was removed from the
plates and serial dilutions were cultured overnight at 37uCo nL B
agar plates to determine the viability of bacteria. In turn, the
monolayers were resuspended in 40 ml of lysis buffer (1% Triton
X-100) and protease inhibitor mix (Complete
TM protease
inhibitors, Roche). This material was subjected to Western
blotting as mentioned above.
Immunogold Labeling and Electronic Microscopy
EPEC E2348/69 strain was grown in LB overnight at 37uC
without shaking and diluted 1:100 into DMEM with 0.56 mg/ml of
eitherCoilAorCoilB,in24-wellplates.Theplateswereincubatedfor
4 h under a 5% CO2 atmosphere.A50 ml droplet of bacterial culture
was applied to nickel EM grids (mesh 200) coated with 0.25%
Formvar resin (Structure Probe, Inc., SPI supplies, PA, USA) for
2 min. Cells were immediately fixed face down for 15 min with 0.1%
buffered glutaraldehyde in PBS (pH 7.3). The grids were washed by
transfer across 6 drops of PBS and blocked in PBS containing 0.2%
bovine serum albumin for 30 min at room temperature. The bacteria
were then incubated on drops of 1:100 polyclonal rabbit antibodies to
EspA [46] in blocking buffer overnight at 4uC. Afterwards, the grids
were washed by transfer across 6 drops of PBS and incubated with
1:50colloidalgold-conjugated goat affinity purified antibody torabbit
IgG (gold particle diameter, 5 nm) (Sigma Chemical Co., USA) for
2 h at room temperature. Grids were then washed with PBS, stained
with 2% uranile acetate and examined by transmission electron
microscopy (TEM) using a Jeol 1200 EXII equipment operating at
85 kV. Fifty EspA filaments were identified and the size was
measured the length is given as an average with a standard deviation.
Statistics
The values are expressed as mean 6 standard error (mean 6
SE). Statistical analysis was carried out using the Student’s t-test,
with a 95% confidence limit; a probability value of P,0.05 was
considered significant.
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